Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIW815 (ADU-S100) + PDR001 in advanced solid tumors/lymphomas
NCT03172936Phase 1Terminated
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Dec 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 1, open-label trial of ADU-S100 in solid tumor and lymphoma (2 arms), sponsored by Novartis. Primary endpoint: Incidence of dose limiting toxicities at 24 months. Started Sep 2017; status: terminated.
02
Drugs
ADU-S100
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03172936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172936.